Oxaflozane

Oxaflozane
Clinical data
Trade namesConflictan
Other namesCERM-1766
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 4-Propan-2-yl-2-[3-(trifluoromethyl)phenyl]morpholine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.043.490
Edit this at Wikidata
Chemical and physical data
FormulaC14H18F3NO
Molar mass273.299 g·mol−1
3D model (JSmol)
SMILES
  • O1CCN(C(C)C)CC1c2cc(C(F)(F)F)ccc2

Oxaflozane (INN) (brand name Conflictan) is an antidepressant and anxiolytic drug that was introduced by Solvay in France in 1982 for the treatment of depression but has since been discontinued.[1][2][3][4] It is a prodrug of flumexadol (N-dealkyloxaflozane; 2-(3-trifluoromethylphenyl)morpholine; CERM-1841 or 1841-CERM), which is reported to act as an agonist of the serotonin 5-HT1A (pKi = 7.1) and 5-HT2C (pKi = 7.5) receptors and, to a much lesser extent, of the 5-HT2A (pKi = 6.0) receptor.[4][5] In addition to its serotonergic properties, oxaflozane may also produce anticholinergic side effects at high doses, namely in overdose.[6]

See also

References

  1. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 909–. ISBN 978-1-4757-2085-3.
  2. ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 766. ISBN 3-88763-075-0.
  3. ↑ Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122. ISBN 0-8155-1144-2.
  4. 1 2 Jean-Pierre Bégué; Daniele Bonnet-Delpon (2 June 2008). Bioorganic and Medicinal Chemistry of Fluorine. John Wiley & Sons. pp. 303–. ISBN 978-0-470-28187-1.
  5. ↑ Leysen DC (February 1999). "Selective 5-HT2C agonists as potential antidepressants". IDrugs. 2 (2): 109–20. PMID 16160946.
  6. ↑ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). "Oxaflozane overdose in a child". Journal of Toxicology. Clinical Toxicology. 30 (1): 123–6. doi:10.3109/15563659208994452. PMID 1542141.

Further reading

  • Rascol A, Maurel H, David J, Layani M (1974). "[Preliminary clinical results of a new non tricyclic antidepressive drug: oxaflozane]". Thérapie (in French). 29 (1): 95–9. PMID 4603757.
  • Hache J, Duchene-Marullaz P, Streichenberger G (1974). "[Pharmacological profile of a new non tricyclic antidepressant: oxaflozane (1,766 Cerm)]". Thérapie (in French). 29 (1): 81–93. PMID 4849381.
  • Constantin M, Pognat JF (1979). "Comparative study of oxaflozane urinary metabolism in man, the dog and the rat. Identification of the principal metabolites". Arzneimittel-Forschung. 29 (1): 109–14. PMID 582104.
  • Bertolino A, palermo M, Porro V (1985). "Un nouvel antidépresseur non tricyclique, l'oxaflozane, dans le traitement des syndromes anxio-dépressifs" [Oxaflozane, a new nontricyclic antidepressant in the treatment of anxiety-depressions syndromes]. Acta Therapeutica. 11 (2): 209–218.
  • Aguglia E (1986). "On the therapetic value of oxaflozane: Its application in the treatment of emotional disturbances of the anxious-depressive type accompanied by somatic manifestations". Acta Therapeutica. 12 (3): 259–268.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.